Trilaciclib, Cemiplimab & GU Updates
Feb 25, 2021•20 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Topics covered:
1. Trilaciclib's approval to minimize bone marrow suppression
2. Cemiplimab's approval for mNSLC with high PD-L1 expression
3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma
4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer
5. More of the same with lenvatinib + pembrolizumab in mRCC
For the best experience, listen in Metacast app for iOS or Android